{"id":"axt107-low-dose","_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"_dailymed":null,"_scrapedAt":"2026-03-28T04:57:30.985Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123157,"model":"claude-sonnet-4-5-20250929"},"description":"AXT107 Low Dose is an investigational therapeutic being developed by AsclepiX Therapeutics, Inc. currently in Phase 1 clinical trials. The drug's molecular target, mechanism of action, and therapeutic indication have not been publicly disclosed at this early stage of development.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT05859776","phase":"PHASE1, PHASE2","title":"Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AsclepiX Therapeutics, Inc.","startDate":"2023-12-19","conditions":"Neovascular Age-related Macular Degeneration","enrollment":15},{"nctId":"NCT04746963","phase":"PHASE1, PHASE2","title":"Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration","status":"TERMINATED","sponsor":"AsclepiX Therapeutics, Inc.","startDate":"2021-02-01","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":3},{"nctId":"NCT04697758","phase":"PHASE1, PHASE2","title":"Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema","status":"TERMINATED","sponsor":"AsclepiX Therapeutics, Inc.","startDate":"2020-12-10","conditions":"Diabetic Macular Edema (DME)","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gersizangatide"],"phase":"phase_1","status":"active","brandName":"AXT107 Low Dose","genericName":"AXT107 Low Dose","companyName":"AsclepiX Therapeutics, Inc.","companyId":"asclepix-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AXT107 is a treatment being studied for Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration, and Neovascular Age-Related Macular Degeneration (nAMD) in clinical trials. The treatment is available in low doses of 0.1 mg, 0.25 mg, and 0.5 mg, as per the clinical trials registered on ClinicalTrials.gov.","enrichmentLevel":2,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}